A novel tumor-targeted therapy using a claudin-4-targeting molecule

Molecular Pharmacology

Volumn 76, Issue 4, 2009, Pages 918-926

  Saeki, Rie ^a   Kondoh, Masuo ^a   Kakutani, Hideki ^a   Tsunoda, Shin Ichi ^c   Mochizuki, Yasuhiro ^d   Hamakubo, Takao ^d   Tsutsumi, Yasuo ^a,c   Horiguchi, Yasuhiko ^b   Yagi, Kiyohito ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CLAUDIN 1; CLAUDIN 2; CLAUDIN 4; CLAUDIN 5; ENTEROTOXIN; PROTEIN SYNTHESIS INHIBITORY FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM CELL; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; FEMALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 70349324335     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.058412     Document Type: Article

References (41)

1. Allen TM and Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818-1822. (Pubitemid 38374867)
2. Anderson JM and Van Itallie CM (1995) Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol 269:G467-G475.
3. Deckert PM (2009) Current constructs and targets in clinical development for antibody-based cancer therapy. Curr Drug Targets 10:158-175.
4. Dunham W (2007) Report sees 7.6 million global 2007 cancer deaths. 2007 Dec 17, Reuters, New York. Available at http://www.reuters.com/article/ healthNews/idUSN1633064920071217.
5. Ebihara C, Kondoh M, Hasuike N, Harada M, Mizuguchi H, Horiguchi Y, Fujii M, and Watanabe Y (2006) Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin. J Pharmacol Exp Ther 316:255-260. (Pubitemid 41832604)
6. Fujita K, Katahira J, Horiguchi Y, Sonoda N, Furuse M, and Tsukita S (2000) Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett 476:258-261. (Pubitemid 30410828)
7. Furuse M and Tsukita S (2006) Claudins in occluding junctions of humans and flies. Trends Cell Biol 16:181-188.
8. Hanna PC, Wieckowski EU, Mietzner TA, and McClane BA (1992) Mapping of functional regions of Clostridium perfringens type A enterotoxin. Infect Immun 60:2110-2114.
9. Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47:3039-3051.
10. Jain RK (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81:570-576.
11. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
12. Katahira J, Inoue N, Horiguchi Y, Matsuda M, and Sugimoto N (1997) Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol 136:1239-1247. (Pubitemid 27421912)
13. Kominsky SL (2006) Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 8:1-11. (Pubitemid 44184255)
14. Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P, and Sukumar S (2004) Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 164:1627-1633. (Pubitemid 38529765)
15. Kondoh M, Masuyama A, Takahashi A, Asano N, Mizuguchi H, Koizumi N, Fujii M, Hayakawa T, Horiguchi Y, and Watanbe Y (2005) A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol Pharmacol 67:749-756. (Pubitemid 40365322)
16. Kreitman RJ (1999) Immunotoxins in cancer therapy. Curr Opin Immunol 11:570-578.
17. Kreitman RJ and Pastan I (2006) Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 7:1301-1311.
18. Long H, Crean CD, Lee WH, Cummings OW, and Gabig TG (2001) Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 61:7878-7881. (Pubitemid 33049378)
19. McClane BA and Chakrabarti G (2004) New insights into the cytotoxic mechanisms of Clostridium perfringens enterotoxin. Anaerobe 10:107-114.
20. Meunier V, Bourrié M, Berger Y, and Fabre G (1995) The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol Toxicol 11:187-194.
21. Michl P, Buchholz M, Rolke M, Kunsch S, Löhr M, McClane B, Tsukita S, Leder G, Adler G, and Gress TM (2001) Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121:678-684. (Pubitemid 32822583)
22. Michl P and Gress TM (2004) Bacteria and bacterial toxins as therapeutic agents for solid tumors. Curr Cancer Drug Targets 4:689-702. (Pubitemid 40013574)
23. Mitic LL and Anderson JM (1998) Molecular architecture of tight junctions. Annu Rev Physiol 60:121-142.
24. Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65:9603-9606.
25. Nichols LS, Ashfaq R, and Iacobuzio-Donahue CA (2004) Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 121:226-230. (Pubitemid 38140127)
26. Ogata M, Chaudhary VK, Pastan I, and FitzGerald DJ (1990) Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem 265:20678-20685. (Pubitemid 120014061)
27. Paperna T, Peoples R, Wang YK, Kaplan P, and Francke U (1998) Genes for the CPE receptor (CPETR1) and the human homolog of RVP1 (CPETR2) are localized within the Williams-Beuren syndrome deletion. Genomics 54:453-459. (Pubitemid 29036232)
28. Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, and Morin PJ (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9:2567-2575. (Pubitemid 36842098)
29. Sakihama T, Sato T, Iwanari H, Kitamura T, Sakaguchi S, Kodama T, and Hamakubo T (2008) A simple detection method for low-affinity membrane protein interactions by baculoviral display. PLoS One 3:e4024.
30. Santin AD, Cané S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, and Pecorelli S (2005) Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res 65:4334-4342. (Pubitemid 40775672)
31. Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, Dvorak HF, and Yarmush ML (1992) A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 52:357-366.
32. Singh U, Mitic LL, Wieckowski EU, Anderson JM, and McClane BA (2001) Comparative biochemical and immunocytochemical studies reveal differences in the effects of Clostridium perfringens enterotoxin on polarized CaCo-2 cells versus Vero cells. J Biol Chem 276:33402-33412. (Pubitemid 37384548)
33. Takahashi A, Komiya E, Kakutani H, Yoshida T, Fujii M, Horiguchi Y, Mizuguchi H, Tsutsumi Y, Tsunoda S, Koizumi N, et al. (2008) Domain mapping of a claudin-4 modulator, the C-terminal region of C-terminal fragment of Clostridium perfringens enterotoxin, by site-directed mutagenesis. Biochem Pharmacol 75:1639-1648.
34. Takahashi A, Kondoh M, Masuyama A, Fujii M, Mizuguchi H, Horiguchi Y, and Watanabe Y (2005) Role of C-terminal regions of the C-terminal fragment of Clostridium perfringens enterotoxin in its interaction with claudin-4. J Control Release 108:56-62. (Pubitemid 41476674)
35. Tsukita S and Furuse M (1999) Occludin and claudins in tight-junction strands: leading or supporting players? Trends Cell Biol 9:268-273. (Pubitemid 29305516)
36. Tsukita S, Yamazaki Y, Katsuno T, Tamura A, and Tsukita S (2008) Tight junction-based epithelial microenvironment and cell proliferation. Oncogene 27:6930-6938.
37. Van Itallie CM, Betts L, Smedley JG 3rd, McClane BA, and Anderson JM (2008) Structure of the claudin-binding domain of Clostridium perfringens enterotoxin. J Biol Chem 283:268-274.
38. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, and Welsh MJ (2003) Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 422:322-326. (Pubitemid 36378360)
39. Waldmann TA (1991) Monoclonal antibodies in diagnosis and therapy. Science 252:1657-1662.
40. Wodarz A and Näthke I (2007) Cell polarity in development and cancer. Nat Cell Biol 9:1016-1024.
41. Zumkeller W and Schofield PN (1995) Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res 15:343-348.